Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Cardin Drake who wrote (28341)	5/21/1998 10:36:00 AM
From: Knighty Tin	Read Replies (3) \| Respond to of 132070

Cardin, Of the ones you mention, Onyx is the only name I have looked at in detail. I kind of like it, but it didn't make my list of the ones I own. The names I like now, in no particular order, are: Genzyme Transgenics-gztc, Genzyme Tissue Repair-genzl, Ligand-lgnd, Medarex-medx, Cell Genysis-cege, Chiron-Chir, Myriad-mygn, Shaman-shmn and, as a catch-all for the industry and to participate in some unlisted ventures, H&Q Health Sciences Investment Fund-HQH, currently selling at a dandy 17.4% discount to its net asset value. My biotech list is smaller than usual because I have sold my gene mapping cos. with the announcement of the Perkin-Elmer machine. Also, though I like the cos. prospects and think the price of the stocks is low, I don't like the overall market and do not believe that these stocks will go up if there is a crash. They will be the first to recover if the science remains excellent, but they are not bullet-proof. MB